U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06992934) titled 'Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors' on April 22.
Brief Summary: Allogeneic hematopoietic stem cell transplantation (aHSCT) is the only curative option for many hematological maligancies. The main cause of death following HSCT is the relapse of the original disease.
Few strategies have been developed to prevent relapse after bone marrow transplantation. New prophylactic strategies are needed to decrease the relapse incidence without increasing the non-relapse mortality in the post-transplant area. Several drugs are currently being explored as maintenance in several AML subgroups such as FLT3 IT...